TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02425020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Protein
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Study: NCT00679432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
Study: NCT00694694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days
Study: NCT00679432

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-MMX® 6 mg
Description: 6 mg/day, 6 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-MMX® 9 mg
Description: 9 mg/day, 9 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol® 400 mg
Description: 2400 mg/day, 400 mg tablets
Study: NCT02657369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg
Study: NCT02201485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon
Study: NCT01841788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Adhesion Patch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Thermal Adhesion Patch

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study: NCT01040975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention targeting MD communication; Summary Report
Description: Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
Study: NCT02308605

Intervention type: DEVICE
Intervention: SMARTCap
Description: The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.

Intervention type: DEVICE
Intervention: SMARTCap
Description: The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.

Intervention type: DEVICE
Intervention: SMARTCap
Description: The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
Study: NCT02562534

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI compatible ElectroCardioGraph
Description: MRI with ECG control for people with healthy heart or heart diseases
Study: NCT00598169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 on Day 1
Study: NCT02562534

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI compatible ElectroCardioGraph
Description: MRI with ECG control for people with healthy heart or heart diseases

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI compatible ElectroCardioGraph
Description: MRI with ECG control for people with healthy heart or heart diseases
Study: NCT02379520

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HPV Specific T Cells
Description: Dose escalation study with 5 dose levels: DL1-1×10\^7 cells/m2, DL2-3×10\^7 cells/m2, and DL3-1×10\^8 cells/m2, DL4- 2 to 3×10\^8 cells/m2, DL5- 0.8 to 1×10\^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion \& nivolumab \& HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) \& no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level.
Study: NCT01411592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multilink
Description: After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Panavia 21 TC
Description: After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
Study: NCT03882346

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LifeLiver
Description: LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
Study: NCT03579550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopic metroplasty intervention arm
Description: One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
Study: NCT04966884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK Inhibitor
Description: 1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months.
Study: NCT02379520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 500mg/m\^2/day x 3 days (on days -4, -3 and -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m\^2/day x 3 days (on days -4, -3, and -2)
Study: NCT01047852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
Study: NCT02379520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg every 2 weeks (+/- 3 days) starting on day -1
Study: NCT01160341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosteron
Description: Testosteron 250mg injection per 3-4 weeks for 6 months
Study: NCT05523323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
Study: NCT02509637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyspnea scale
Description: Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
Study: NCT05523323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
Study: NCT02509637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptability and tolerance
Description: patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
Study: NCT02932332

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High-flow Oxygen
Description: Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow Oxygen
Description: Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
Study: NCT05523323

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
Study: NCT02509637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptability and tolerance
Description: patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptability and tolerance
Description: patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Difficulty sputum
Description: Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
Study: NCT02509637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Difficulty sputum
Description: Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Difficulty sputum
Description: Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
Study: NCT02932332

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study: NCT00915564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
Study: NCT01901081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMES
Description: Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months.
Study: NCT05523323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
Study: NCT03801512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
Study: NCT03778242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study: NCT03010631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Lubiprostone Capsule, Fasted
Description: Lubiprostone soft gelatin capsule administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Lubiprostone Capsule, Fasted
Description: Lubiprostone soft gelatin capsule administered under fasted conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fed
Description: Lubiprostone sprinkle formulation administered under fed conditions
Study: NCT01400620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6N4
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IZN-6N4
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
Study: NCT00010608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
Study: NCT03801512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Inject investigators Platelet Rich Plasma at neuritis nerve roots
Study: NCT03010631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fed
Description: Lubiprostone sprinkle formulation administered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study: NCT00411216

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control exercises
Description: saccadic eye movements against a plain background; no head movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze stabilization exercises
Description: adaptation and substitutin exercises encorporating retinal lsip and head movements
Study: NCT02828943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMT with High Resistance EMT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IMT with Low Resistance EMT
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140
Description: Administered by IM injection
Study: NCT04426916

Intervention type: OTHER
Intervention: Spondylolisthesis
Description: Spondylolisthesis at a single level
Study: NCT03244046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
Study: NCT00010608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake